Literature DB >> 29204843

Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.

Enea Spada1, Giovanni Rezza2, Anna Rosa Garbuglia3, Flavia Lucia Lombardo4, Ornella Zuccaro5, Francesca Menniti Ippolito4, Elisabetta Cupellaro6, Stefania Capone7, Maria Rosaria Capobianchi3, Alfredo Nicosia7,8,9, Riccardo Cortese9, Antonella Folgori7, Alfonso Mele10.   

Abstract

So far, only three small outdated studies have investigated hepatitis C virus (HCV) incidence and risk factors among illicit drug users (DUs) in Italy. Thus, during 2007-2010, we conducted a prospective cohort study among DUs attending 17 Italian rehabilitation centers serving urban areas. Two hundred eighty-four HCV-uninfected DUs were prospectively followed by interview and anti-HCV antibody and RNA testing every 6 months. Incidence was calculated using the person-years method. Infection predictors were assessed by time-dependent Cox analysis. Participants were mostly male (83.4%), under opioid substitution therapy (OST) (78.9%), non-injecting DUs (67.9%), and with a mean age of 30.8. Ninety-one of 224 DUs initially under OST interrupted treatment during the follow-up. Overall HCV incidence was 5.83/100 person-years at risk (PYAR) [95% confidence intervals (CI), 3.63-9.38]. The incidence did not significantly differ according the participants' sociodemographic characteristics or the degree of urbanization of the towns involved in the study. The incidence was higher for DUs under than for those not under OST (6.23 vs 4.50/100 PYAR; p = 0.681). Incidence was also higher for those with than for those without OST interruption (7.17 vs 5.04/100 PYAR; p = 0.55). However, all these differences were non-significant. At last follow-up visit, a significant decrease in frequency of sharing equipment for preparation/using drugs (by injection or not) was observed by analyzing either the whole cohort or DUs under OST only. Anti-HCV seroconversion resulted independently associated with sharing drug preparation/use equipment, backloading, having a HCV-positive sexual partner, or household and (marginally) intravenous injection. In this study, HCV incidence was non-negligible and OST seemed to lack effectiveness in reducing it. In Italy, implementation of combined harm reduction interventions and antiviral treatment of chronically infected DUs would be needed.

Entities:  

Keywords:  Hepatitis C virus; Illicit drug use; Incidence; Opioid substitution treatment; Risk factors; Seroconversion

Mesh:

Substances:

Year:  2018        PMID: 29204843      PMCID: PMC5862696          DOI: 10.1007/s11524-017-0207-5

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  39 in total

Review 1.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

2.  Low incidence of hepatitis C virus transmission between spouses: a prospective study.

Authors:  J H Kao; C J Liu; P J Chen; W Chen; M Y Lai; D S Chen
Journal:  J Gastroenterol Hepatol       Date:  2000-04       Impact factor: 4.029

Review 3.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

Review 4.  Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.

Authors:  Norah Palmateer; Jo Kimber; Matthew Hickman; Sharon Hutchinson; Tim Rhodes; David Goldberg
Journal:  Addiction       Date:  2010-03-02       Impact factor: 6.526

5.  Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.

Authors:  Charlotte H S B van den Berg; Colette Smit; Margreet Bakker; Ronald B Geskus; Ben Berkhout; Suzanne Jurriaans; Roel A Coutinho; Katja C Wolthers; Maria Prins
Journal:  Eur J Epidemiol       Date:  2007-03-03       Impact factor: 8.082

6.  Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects.

Authors:  B Galeazzi; A Tufano; E Barbierato; F Bortolotti
Journal:  Liver       Date:  1995-08

7.  Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study.

Authors:  Carmen Vandelli; Francesco Renzo; Luisa Romanò; Sergio Tisminetzky; Marisa De Palma; Tommaso Stroffolini; Ezio Ventura; Alessandro Zanetti
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

8.  Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.

Authors:  Handan Wand; Donna Spiegelman; Matthew Law; Bin Jalaludin; John Kaldor; Lisa Maher
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

Review 9.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

10.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.

Authors:  Charlotte Van Den Berg; Colette Smit; Giel Van Brussel; Roel Coutinho; Maria Prins
Journal:  Addiction       Date:  2007-09       Impact factor: 6.526

View more
  7 in total

1.  Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic.

Authors:  Valerio Rosato; Riccardo Nevola; Vincenza Conturso; Pasquale Perillo; Davide Mastrocinque; Annalisa Pappalardo; Teresa Le Pera; Ferdinando Del Vecchio; Ernesto Claar
Journal:  Biology (Basel)       Date:  2022-05-24

2.  Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection.

Authors:  Loreta A Kondili; Lucia Craxì; Massimo Andreoni; Francesco S Mennini; Homie Razavi
Journal:  Liver Int       Date:  2022-05       Impact factor: 8.754

3.  Optimization of hepatitis C virus screening strategies by birth cohort in Italy.

Authors:  Loreta A Kondili; Ivane Gamkrelidze; Sarah Blach; Andrea Marcellusi; Massimo Galli; Salvatore Petta; Massimo Puoti; Stefano Vella; Homie Razavi; Antonio Craxi; Francesco S Mennini
Journal:  Liver Int       Date:  2020-04-02       Impact factor: 5.828

4.  Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infections among people who inject drugs in Kuwait: A cross-sectional study.

Authors:  Haya Altawalah; Sahar Essa; Sayeh Ezzikouri; Widad Al-Nakib
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

5.  Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients.

Authors:  Olivera Djuric; Marco Massari; Marta Ottone; Giorgia Collini; Pamela Mancuso; Massimo Vicentini; Antonio Nicolaci; Angela Zannini; Alessandro Zerbini; Valeria Manicardi; Loreta A Kondili; Paolo Giorgi Rossi
Journal:  Infect Agent Cancer       Date:  2021-01-19       Impact factor: 2.965

6.  Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.

Authors:  Chiedozie Arum; Hannah Fraser; Andreea Adelina Artenie; Sandra Bivegete; Adam Trickey; Michel Alary; Jacquie Astemborski; Jennifer Iversen; Aaron G Lim; Louis MacGregor; Meghan Morris; Jason J Ong; Lucy Platt; Rachel Sack-Davis; Daniela K van Santen; Sunil S Solomon; Vana Sypsa; Jorge Valencia; Wijnand Van Den Boom; Josephine G Walker; Zoe Ward; Jack Stone; Peter Vickerman
Journal:  Lancet Public Health       Date:  2021-03-26

7.  Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy.

Authors:  Alessandra Mangia; Maria Franca Rina; Antonio Canosa; Valeria Piazzolla; Maria Maddalena Squillante; Ernesto Agostinacchio; Giovanna Cocomazzi; Egidio Visaggi; Nazario Augello; Camilla Iannuzziello; Mattia Falcone; Angelo De Giorgi; Fausto Campanozzi
Journal:  United European Gastroenterol J       Date:  2021-10-26       Impact factor: 4.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.